FilingSEC EDGAR6-K
Radiopharm Theranostics Receives Approval to Increase Dose in 177Lu-RAD202 Phase 1 Trial
· SEC accepted
StagePhase 1
Filing content
Following a positive recommendation from the DSMC, the company will advance its 177Lu-RAD202 Phase 1 trial to the 180mCi dose level.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…